BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 24948577)

  • 1. Long-term, low-dose erythromycin monotherapy for Mycobacterium avium complex lung disease: a propensity score analysis.
    Komiya K; Kurashima A; Ihi T; Nagai H; Matsumoto N; Mizunoe S; Ishii H; Takahashi O; Ohta K; Kudoh S; Kadota J
    Int J Antimicrob Agents; 2014 Aug; 44(2):131-5. PubMed ID: 24948577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association between erythromycin monotherapy for Mycobacterium avium complex lung disease and cross-resistance to clarithromycin: A retrospective case-series study.
    Hosono Y; Kitada S; Yano Y; Mori M; Miki K; Miki M; Yoshimura K; Kagawa H; Oshitani Y; Yokota S
    J Infect Chemother; 2018 May; 24(5):353-357. PubMed ID: 29361415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors that affect sputum conversion and treatment outcome in patients with Mycobacterium avium-intracellulare complex pulmonary disease.
    Ye JJ; Wu TS; Chiang PC; Lee MH
    J Microbiol Immunol Infect; 2007 Aug; 40(4):342-8. PubMed ID: 17712469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of drug treatment outcome in clarithromycin-resistant Mycobacterium avium complex lung disease.
    Kadota T; Matsui H; Hirose T; Suzuki J; Saito M; Akaba T; Kobayashi K; Akashi S; Kawashima M; Tamura A; Nagai H; Akagawa S; Kobayashi N; Ohta K
    BMC Infect Dis; 2016 Jan; 16():31. PubMed ID: 26818764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical features and treatment history of clarithromycin resistance in M. avium-intracellulare complex pulmonary disease patients].
    Kuwabara K; Tsuchiya T
    Nihon Kokyuki Gakkai Zasshi; 2007 Aug; 45(8):587-92. PubMed ID: 17763685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic drug monitoring in the treatment of Mycobacterium avium complex lung disease.
    Koh WJ; Jeong BH; Jeon K; Lee SY; Shin SJ
    Am J Respir Crit Care Med; 2012 Oct; 186(8):797-802. PubMed ID: 22878282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease.
    Griffith DE; Brown-Elliott BA; Langsjoen B; Zhang Y; Pan X; Girard W; Nelson K; Caccitolo J; Alvarez J; Shepherd S; Wilson R; Graviss EA; Wallace RJ
    Am J Respir Crit Care Med; 2006 Oct; 174(8):928-34. PubMed ID: 16858014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment.
    van Ingen J; Egelund EF; Levin A; Totten SE; Boeree MJ; Mouton JW; Aarnoutse RE; Heifets LB; Peloquin CA; Daley CL
    Am J Respir Crit Care Med; 2012 Sep; 186(6):559-65. PubMed ID: 22744719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates.
    Kobashi Y; Yoshida K; Miyashita N; Niki Y; Oka M
    J Infect Chemother; 2006 Aug; 12(4):195-202. PubMed ID: 16944258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of clarithromycin and ethambutol for Mycobacterium avium complex pulmonary disease. A preliminary study.
    Miwa S; Shirai M; Toyoshima M; Shirai T; Yasuda K; Yokomura K; Yamada T; Masuda M; Inui N; Chida K; Suda T; Hayakawa H
    Ann Am Thorac Soc; 2014 Jan; 11(1):23-9. PubMed ID: 24298907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Outcome of pulmonary Mycobacterium avium complex (MAC) disease treated with clarithromycin (CAM)-containing regimens].
    Shirai M; Hayakawa H; Nakano Y; Kuroishi S; Nakano Y; Todate A; Suda T; Chida K
    Nihon Kokyuki Gakkai Zasshi; 2004 Oct; 42(10):875-9. PubMed ID: 15566000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective treatment for clarithromycin-resistant Mycobacterium avium complex lung disease.
    Adachi Y; Tsuyuguchi K; Kobayashi T; Kurahara Y; Yoshida S; Kagawa T; Hayashi S; Suzuki K
    J Infect Chemother; 2020 Jul; 26(7):676-680. PubMed ID: 32171660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macrolide/Azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease.
    Wallace RJ; Brown-Elliott BA; McNulty S; Philley JV; Killingley J; Wilson RW; York DS; Shepherd S; Griffith DE
    Chest; 2014 Aug; 146(2):276-282. PubMed ID: 24457542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Macrolide-Resistant Mycobacterium avium Complex Lung Disease: Analysis of 102 Consecutive Cases.
    Morimoto K; Namkoong H; Hasegawa N; Nakagawa T; Morino E; Shiraishi Y; Ogawa K; Izumi K; Takasaki J; Yoshiyama T; Hoshino Y; Matsuda S; Hayashi Y; Sasaki Y; Ishii M; Kurashima A; Nishimura T; Betsuyaku T; Goto H;
    Ann Am Thorac Soc; 2016 Nov; 13(11):1904-1911. PubMed ID: 27513168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease.
    Jeong BH; Jeon K; Park HY; Kim SY; Lee KS; Huh HJ; Ki CS; Lee NY; Shin SJ; Daley CL; Koh WJ
    Am J Respir Crit Care Med; 2015 Jan; 191(1):96-103. PubMed ID: 25393520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Rapid Screening Assay for Clarithromycin-Resistant Mycobacterium avium Complex Using Melting Curve Analysis with Nonfluorescent Labeled Probes.
    Aoki A; Jinno H; Ogawa K; Nakagawa T; Inagaki T; Wajima T; Okamoto Y; Uchiya KI
    Microbiol Spectr; 2023 Feb; 11(1):e0432622. PubMed ID: 36622171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycobacterium avium complex pulmonary disease: management options in HIV-negative patients.
    Ramirez J; Mason C; Ali J; Lopez FA
    J La State Med Soc; 2008; 160(5):248-54; quiz 254, 293. PubMed ID: 19048978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of Macrolide Resistance and Reinfection in Refractory Mycobacterium avium Complex Lung Disease.
    Jhun BW; Kim SY; Moon SM; Jeon K; Kwon OJ; Huh HJ; Ki CS; Lee NY; Shin SJ; Daley CL; Koh WJ
    Am J Respir Crit Care Med; 2018 Nov; 198(10):1322-1330. PubMed ID: 29877739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex.
    Griffith DE; Brown BA; Cegielski P; Murphy DT; Wallace RJ
    Clin Infect Dis; 2000 Feb; 30(2):288-92. PubMed ID: 10671330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Characteristics, Treatment Outcomes, and Resistance Mutations Associated with Macrolide-Resistant Mycobacterium avium Complex Lung Disease.
    Moon SM; Park HY; Kim SY; Jhun BW; Lee H; Jeon K; Kim DH; Huh HJ; Ki CS; Lee NY; Kim HK; Choi YS; Kim J; Lee SH; Kim CK; Shin SJ; Daley CL; Koh WJ
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6758-6765. PubMed ID: 27572413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.